[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BrightPath Biotherapeutics Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100644052","phase-1-a-phase-i-open-label-multicenter-study-to-evaluate-the-safety-and-tolerability-of-bp2202-in-patients-with-relapsedrefractory-multiple-myeloma-100644052",false,"NCT07667868","A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed\u002FRefractory Multiple Myeloma","A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Diagnosis of Multiple Myeloma with relapsed or refractory disease.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Adequate organ function.\n* Have measurable disease\n\nExclusion Criteria:\n\n* Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.\n* Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.","ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed\u002FRefractory Multiple Myeloma.",[26],"Relapsed\u002FRefractory Multiple Myeloma (RRMM)","NOT_YET_RECRUITING","2026-06-29",{"date":30,"type":31},"2026-07-01","ACTUAL",{"date":33,"type":20},"2026-10-01",{"date":35,"type":20},"2028-12-31",{"name":37,"class":38},"BrightPath Biotherapeutics Co., Ltd.","INDUSTRY",""]